SPY продолжает вчерашнее падение
Ближайший уровень поддержки по SPY – 198.40 уровень сопротивления – 198.60
CLX продажа ниже 97
UTHR продажа ниже 134
SFLY продажа ниже 50
CXO покупка выше 127
YELP при удержании 71 покупка, ниже продажа
UBNT покупка при удержании 38
Gapping up/down: SLXP +8% and CF +7% on M&A news; miners trading higher, TKMR +10% on Ebola collaboration news; ASNA -11% and KMX -6% after earnings, Tax inversion names trading lower, DKS -6% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: SUPN +9.5%, MM +1.7%, (also, to acquire Nexage for ~$107.5 mln)
M&A news: SLXP +8.2% (Allergan (AGN) plans to reject offer from Actavis (ACT) and may now bid for SLXP itself, according to reports), CF +7.2% (Yara ASA confirms discussions with CF (CF) regarding potential merger of equals)
Select metals/mining stocks trading higher: HMY +3.4%, GOLD +2.3%, SLW +1.9%, AU +1.9%, GG +1.6%, ABX +1.4%, NEM +1.4%, GDX +1.4%, GLD +1.2%, RIO +0.9%, BHP +0.8%
Other news: SYN +36% (still checking), NXTD +24.5% (cont momentum higher), TTOO +18.1% (announced FDA approval of first direct blood test for detection of five yeast pathogens that cause bloodstream infections), RWLK +11% (announces reimbursement coverage by major German insurance company ), SAEX +9.9% (announced $40 mln of new project awards), TKMR +9.6% (is collaborating with an international consortium to provide an RNAi based investigational therapeutic for expedited clinical studies in West Africa), NAVB +7.1% (Awarded $1.67 mln Fast Track NIH SBIR Grant for Evaluation of Lymphoseek in Cervical Cancer), JRJC +6.6% (entered into a strategic partnership agreement with Zhongshan Securities), ECYT +3.6% (announces late-breaking abstract presentation on randomized, phase II trial comparing vintafolide versus vintafolide plus docetaxel, versus docetaxel alone in second-line treatment of folate-receptor-positive non-small cell lung cancer patients at the European Society for Medical Oncology Conference), MBLY +3.4% (favorable commentary on Monday's Mad Money), HLF +2.7% (following 12%+ move lower on some chatter that Icahn is unwinding his position; after the close Gasparino tweeting that sources say Icahn has not sold any of his HLF stake), DRL +2.2% (co stated its remains confident in the rule of law and that it will prevail' as DRL vs. Hacienda trial concluded), CNET +1.9% (cont momentum), PHG +1.7% (establishes two companies in Lighting solutions and in HealthTech; sees 2H adjusted EBITA slightly below same period last year), MGA +1.7% (expands in India; targeting start of volume production in 2015), DRI +1.4% (issues open letter to shareholders; recommends darden shareholders vote 'for all' on the BLUE Proxy Card ), ASTM +1.1% (Great Point Partners discloses 9.99% stake in 13G filing), LDOS +1% (awarded contract by Naval Medical Logistics Command)
Analyst comments: SGMO +4% (initiated with a Buy at Jefferies), NRG +1.8% (resumed with a Buy at Deutsche Bank), BKU +1.6% (resumed with a Outperform at Wells Fargo), FOE +1.2% (upgraded to Buy from Hold at KeyBanc Capital Mkts), FRC +1% (resumed with a Outperform at Wells Fargo)
Gapping down
In reaction to disappointing earnings/guidance: ASNA -11.1%, ALCS -6.9%, KMX -6.3%
M&A news: BUD -1.1% (cont spec surrounding M&A)
Select Tax Inversion related names showing weakness: SHPG -5.2%, AZN -4.8%, COV -3.9%, SNN -3.7%, MDT -3.7%, ABT -3.3%, BKW -1.8%, MYL -1.8%, PFE -1.8%, PRGO -1.3%, VRX -1.1%
Other news: MTL -28.4% (continued bankruptcy concerns), AVNR -7.5% (announced offering of $200 mln of common stock), GEL -4.9% (announces public offering of 4.0 mln common units), ALIM -2.8% (disclosed sales agreement to issue and sell $35 mln common stock), TSLA -1.8% (cont weakness), YHOO -1.7% (cont weakness post BABA IPO), BABA -1.6% (cont weakness post IPO), SYY -1.5% (may face antitrust lawsuit over US Foods deal, according to reports), TOT -1.4% (trading lower in Europe following news out yesterday afternoon), HCLP -1.4% (unfavorable commentary on Monday's Mad Money)
Analyst comments: DKS -5.9% (downgraded to Mkt Perform from Outperform at William Blair ), ONNN -3.1% (downgraded to Neutral from Overweight at JP Morgan), BBBY -1.3% (downgraded to Mkt Perform from Outperform at William Blair), CLX -1.2% (downgraded to Neutral from Buy at Citigroup), GMAN -0.6% (downgraded to Hold from Buy at Canaccord Genuity)
Оригинал статьи: gtstocks.com/analytics-23-09-2014.html
CLX продажа ниже 97
UTHR продажа ниже 134
SFLY продажа ниже 50
CXO покупка выше 127
YELP при удержании 71 покупка, ниже продажа
UBNT покупка при удержании 38
Gapping up/down: SLXP +8% and CF +7% on M&A news; miners trading higher, TKMR +10% on Ebola collaboration news; ASNA -11% and KMX -6% after earnings, Tax inversion names trading lower, DKS -6% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: SUPN +9.5%, MM +1.7%, (also, to acquire Nexage for ~$107.5 mln)
M&A news: SLXP +8.2% (Allergan (AGN) plans to reject offer from Actavis (ACT) and may now bid for SLXP itself, according to reports), CF +7.2% (Yara ASA confirms discussions with CF (CF) regarding potential merger of equals)
Select metals/mining stocks trading higher: HMY +3.4%, GOLD +2.3%, SLW +1.9%, AU +1.9%, GG +1.6%, ABX +1.4%, NEM +1.4%, GDX +1.4%, GLD +1.2%, RIO +0.9%, BHP +0.8%
Other news: SYN +36% (still checking), NXTD +24.5% (cont momentum higher), TTOO +18.1% (announced FDA approval of first direct blood test for detection of five yeast pathogens that cause bloodstream infections), RWLK +11% (announces reimbursement coverage by major German insurance company ), SAEX +9.9% (announced $40 mln of new project awards), TKMR +9.6% (is collaborating with an international consortium to provide an RNAi based investigational therapeutic for expedited clinical studies in West Africa), NAVB +7.1% (Awarded $1.67 mln Fast Track NIH SBIR Grant for Evaluation of Lymphoseek in Cervical Cancer), JRJC +6.6% (entered into a strategic partnership agreement with Zhongshan Securities), ECYT +3.6% (announces late-breaking abstract presentation on randomized, phase II trial comparing vintafolide versus vintafolide plus docetaxel, versus docetaxel alone in second-line treatment of folate-receptor-positive non-small cell lung cancer patients at the European Society for Medical Oncology Conference), MBLY +3.4% (favorable commentary on Monday's Mad Money), HLF +2.7% (following 12%+ move lower on some chatter that Icahn is unwinding his position; after the close Gasparino tweeting that sources say Icahn has not sold any of his HLF stake), DRL +2.2% (co stated its remains confident in the rule of law and that it will prevail' as DRL vs. Hacienda trial concluded), CNET +1.9% (cont momentum), PHG +1.7% (establishes two companies in Lighting solutions and in HealthTech; sees 2H adjusted EBITA slightly below same period last year), MGA +1.7% (expands in India; targeting start of volume production in 2015), DRI +1.4% (issues open letter to shareholders; recommends darden shareholders vote 'for all' on the BLUE Proxy Card ), ASTM +1.1% (Great Point Partners discloses 9.99% stake in 13G filing), LDOS +1% (awarded contract by Naval Medical Logistics Command)
Analyst comments: SGMO +4% (initiated with a Buy at Jefferies), NRG +1.8% (resumed with a Buy at Deutsche Bank), BKU +1.6% (resumed with a Outperform at Wells Fargo), FOE +1.2% (upgraded to Buy from Hold at KeyBanc Capital Mkts), FRC +1% (resumed with a Outperform at Wells Fargo)
Gapping down
In reaction to disappointing earnings/guidance: ASNA -11.1%, ALCS -6.9%, KMX -6.3%
M&A news: BUD -1.1% (cont spec surrounding M&A)
Select Tax Inversion related names showing weakness: SHPG -5.2%, AZN -4.8%, COV -3.9%, SNN -3.7%, MDT -3.7%, ABT -3.3%, BKW -1.8%, MYL -1.8%, PFE -1.8%, PRGO -1.3%, VRX -1.1%
Other news: MTL -28.4% (continued bankruptcy concerns), AVNR -7.5% (announced offering of $200 mln of common stock), GEL -4.9% (announces public offering of 4.0 mln common units), ALIM -2.8% (disclosed sales agreement to issue and sell $35 mln common stock), TSLA -1.8% (cont weakness), YHOO -1.7% (cont weakness post BABA IPO), BABA -1.6% (cont weakness post IPO), SYY -1.5% (may face antitrust lawsuit over US Foods deal, according to reports), TOT -1.4% (trading lower in Europe following news out yesterday afternoon), HCLP -1.4% (unfavorable commentary on Monday's Mad Money)
Analyst comments: DKS -5.9% (downgraded to Mkt Perform from Outperform at William Blair ), ONNN -3.1% (downgraded to Neutral from Overweight at JP Morgan), BBBY -1.3% (downgraded to Mkt Perform from Outperform at William Blair), CLX -1.2% (downgraded to Neutral from Buy at Citigroup), GMAN -0.6% (downgraded to Hold from Buy at Canaccord Genuity)
Оригинал статьи: gtstocks.com/analytics-23-09-2014.html
0 комментариев